15 results
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
21 Sep 20
Other Events
7:14am
reactions in breastfed children, advise women not to breastfeed during treatment with TIBSOVO® and for at least 1 month after the last dose.
Please see
8-K
EX-99.2
AGIO
Agios Pharmaceuticals Inc
9 Dec 19
Agios EstablishesProof-of-Concept for Mitapivat inNon-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
4:02pm
are excreted in human milk and because of the potential for adverse reactions in breastfed children, advise women not to breastfeed during treatment
8-K
EX-99.1
5d9i99lbuaysd
22 Nov 19
Other Events
5:01pm
8-K
EX-99.1
hedb0m 298o7fs
30 Sep 19
Other Events
11:13am
8-K
EX-99.1
z70ych4u
3 Jun 19
Other Events
4:02pm
8-K
EX-99.1
vgrq4fzmwd2wdzfhu6bw
15 May 19
Achieved its Primary Endpoint in Previously Treated IDH1 Mutant Cholangiocarcinoma
4:13pm
8-K
EX-99.1
5hxuj9oz1lb
2 May 19
Other Events
3:24pm
8-K
EX-99.1
hmmafhmlk5
3 Dec 18
Other Events
4:03pm
8-K
EX-99.2
72fbn2yo1liclwhb 4n
3 Dec 18
Other Events
4:03pm
8-K
EX-99.1
rx75zsknpch1ee6kpgzn
20 Jul 18
FDA Grants Approval of TIBSOVO®, the First Oral, Targeted Therapy for Adult Patients
11:21am
8-K
EX-99.1
220ml5 920igp1xt9t
16 Oct 15
Regulation FD Disclosure
12:00am
8-K
EX-99.1
1qpbdvz3ckv63fsjl4dl
17 Apr 14
Other Events
12:00am
- Prev
- 1
- Next